Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The event, scheduled for Sept. 16 at 8:30 a.m. EDT, will be webcast live, with a replay available on the Events & Presentations page of the company's investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
The presentation comes at a critical time for Helus Pharma, a clinical-stage pharmaceutical company founded in 2019 that is focused on developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs are intended to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, the company aims to improve the treatment landscape by providing durable improvements in mental health.
Helus Pharma's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD) and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation is significant because it is reserved for drugs that may offer substantial improvement over existing therapies for serious conditions. MDD affects millions worldwide, and current treatments often take weeks to work and can have side effects that lead to discontinuation. A new option with a novel mechanism could change the standard of care if approved.
The company is also developing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder (GAD). Anxiety disorders are among the most common mental health conditions, and many patients do not achieve adequate relief with existing medications. A successful NSA for GAD would represent a major advance in a field that has seen few innovations in recent decades.
Halstead's participation in the Morgan Stanley conference is important for several reasons. First, it provides a platform for Helus Pharma to present its clinical progress and vision to a global audience of investors, analysts, and healthcare professionals. The conference is one of the most prestigious in the healthcare sector, and a fireside chat allows for a detailed discussion of the company's strategy, data, and upcoming milestones. Second, it may increase visibility for the company's NASDAQ and Cboe Canada listings, potentially attracting new institutional investors. Third, it signals confidence in the company's pipeline at a time when the psychedelic-inspired medicine sector is under intense scrutiny. Positive data and regulatory designations can differentiate Helus Pharma from competitors.
The broader implications extend beyond the company. If Helus Pharma's NSAs succeed in late-stage trials, they could offer new hope for patients with treatment-resistant depression and anxiety. The Breakthrough Therapy Designation for HLP003 accelerates the FDA's review process, meaning that if the data support approval, patients could gain access sooner. The company's research portfolio of investigational NSAs also suggests a long-term commitment to innovation in mental health, an area where the need for new treatments is urgent. The webcast and replay will allow stakeholders who cannot attend in person to follow the discussion, further broadening the reach of the announcement.
For company updates and to learn more about Helus Pharma, visit www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
